SEC Filings
Prime Medicine Offering Expands Share Base — Robert Nelsen Reports An 8.4% Beneficial Stake
The reporting shareholders said they made no common-stock transactions during the preceding 60 days.
Prime Medicine (PRME) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
The reporting shareholders said they made no common-stock transactions during the preceding 60 days.
SEC Filings
The investment manager reported more than 10 million shares in the developer of DNA-editing medicines.
SEC Filings
A completed offering brought approximately $134.7 million in net proceeds, with liver-trial results and an approval application planned for 2027.
SEC Filings
The new shares account for about 17% of the stated post-offering total, with initial liver-disease trial data expected in 2027.
SEC Filings
Prime expects funding to last into 2027 and plans an approval application for its chronic granulomatous disease treatment.